Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded
natural killer (NK) cells when combined with standard dosing of ch14.18 and will assess the
feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells
with ch14.18, for treatment of children with refractory or recurrent neuroblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Collaborators:
M.D. Anderson Cancer Center Nationwide Children's Hospital United Therapeutics